NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
The Danish biotech and healthcare stocks delivered a return of 5.1%, while the Nordic healthcare stocks fell 1.4%. Cessatech and Biosergen delivered +40% returns each following a partner deal and encouraging study results. Acarix secured another order, while the CEO of Zealand Pharma sold shares worth more than MDKK 30. Finally, SynAct Pharma posted clinical results in a scientific journal supporting AP1189.
12 of the 22 Danish biotech companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 354% return and Odinwell AB was the best Nordic healthcare investment last week. Five Danish healthcare stocks with +100% YTD return.
Danish company news
Acarix Secures Order with National Concierge Healthcare Organization (Link)
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024 (Link)
Biosergen have completed treatment of the first patient with BSG005 (Link)
Biosergen publishes interim report for second quarter 2024 (Link)
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001 (Link)
No news the past week
No news the past week
No news the past week
No news the past week
ExpreS2ion announces publication of sponsored research reports (Link)
FluoGuide appoints Jens Ellrich as Chief Medical Officer (Link)
FluoGuide A/S publishes interim report for the period January – June 2024 (Link)
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Link)
Deutsche Bank lowered their price target from DKK 3,000 to DKK 2,500
No news the past week
No news the past week
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (Link)
IO Biotech Announces Participation in Upcoming Investor Conferences (Link)
PILA PHARMA publishes interim report (1 January – 30 June 2024) (Link)
Saniona publishes its interim report for the second quarter of 2024 (Link)
Scandion Oncology – Interim Report Q2 2024 (Link)
First scientific publication showing treatment potential of a pro-resolving compound in human virus infection (Link)
No news the past week
Zealand Pharma’s CEO sold 35,000 shares at DKK 878 corresponding to MDKK 30.7 (Link)
No news the past week
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a return of 5.1%. The high return was mainly driven by Cessatech and Biosergen rising 40-47%. Biosergen announced the treatment of the first patient with BSG005 and called it a “success both in terms of efficacy and safety”. Cessatech, on the other hand, announced an exclusive commercialization agreement with Proveca for CT001. The deal covers all territories except the U.S. This means Cessatech can focus on the development of the drug rather than the commercialization as Proveca will be the marketing authorization holder. Zealand Pharma rose 2% although their CEO sold shares worth more than MDKK 30. Acarix secured a new order, and SynAct Pharma posted clinical and preclinical data in a scientific journal supporting AP1189 to control virus-induced inflammation.
Gubra remains the best-performing stock year-to-date with a return of 354%. Zealand Pharma, Pila Pharma, CS Medica, Y-mAbs Therapeutics have also delivered returns in excess of 100% in 2024.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 1.4% to 69,74. The index has had a strong performance since the beginning of April and it has now surpassed the KPNGX index. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while it has outperformed the broader Nordic growth exchanges by a couple of percentages.
The index development for the KPHC index the past year
40-50% in weekly return for the Nordic healthcare stocks
Odinwell AB (50%) specializes in the development of medical devices addressed to wound care management. The company is developing a platform for wound care with associated technological aids to analyze and facilitate the process around wound care management. Odinwell announced that they have moved forward and can now build complete systems of the bacteria sensor from sensor node to screen.
Cessatech A/S (47%) specializes in the development of medical devices addressed to wound care management. The company is developing a platform for wound care with associated technological aids to analyze and facilitate the process around wound care management. In addition to the main business, associated services are also offered. announced an exclusive commercialization agreement with Proveca for CT001.
Biosergen AB (40%) specializes in the research and development of various pharmaceuticals. The product portfolio includes, for example, the company’s product BSG005, a fungicidal pharmaceutical in the clinical phase. In addition to the main business, service and associated ancillary services are also offered. The company announced the treatment of the first patient with BSG005 and called it a “success both in terms of efficacy and safety”.
Sources: Refinitiv Eikon, Cision, Nordnet & company websites.
